The Latest Research on Hormone Receptor-Positive (HR+) MBC
Hormone receptor-positive (ER+ and/or PR+) MBC is typically treated with hormone therapy plus other therapies. Read below for the latest research on treatments,...
Read MoreSide Effects of Radiation Therapy for Brain Mets
Because radiation therapy is a standard treatment option for people with brain mets, it is helpful to know what side effects you might experience during and after...
Read MoreOther MBC Resources
ABCD: After Breast Cancer Diagnosis Provides phone-based one-to-one mentoring to those affected by breast cancer as well as a personalized mentor matching service...
Read MoreMetastatic Breast Cancer in the LGBTQI Communities
Little is known about metastatic breast cancer in the lesbian, bisexual, gay, trans, queer, and intersex (LGBTQI) community. However, the available research...
Read MoreExpanded Access
Expanded Access (EA) or “compassionate use” is an FDA-regulated pathway allowing a patient to receive an investigational drug outside of a clinical...
Read More2021 Update on Metastatic Triple Negative Breast Cancer Treatment
Triple-negative breast cancer (TNBC) is a breast cancer subtype that tests negative for estrogen receptors (ER), progesterone receptors (PR), and human...
Read MoreScreening for Breast Cancer Brain Metastases
Breast cancer brain metastases (BCBM) screening is when an imaging test, such as an MRI, is used to look for BCBM in a person who is not experiencing symptoms of...
Read MoreParticipating in a Trial: Patient Voices
There are many ways that medical professionals educate patients and the public about breast cancer clinical trials. One of the most effective ways of increasing...
Read MoreFDA Approves MARGENZA
On December 16, 2020, the FDA approved margetuximab-cmkb (MARGENZA®, MacroGenics) in combination with chemotherapy, for the treatment of patients with metastatic...
Read MoreSEARCH OUR SITE
for past articles or specific information.